Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Effect of Dapagliflozin, an SGLT-2 Inhibitor, on the Counterregulatory Response to Hypoglycemia in Individuals With Type 1 Diabetes

NCT03704818 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT03704818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03704818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Effect of Dapagliflozin, an SGLT-2 Inhibitor, on the Counterregulatory Response to Hypoglycemia in Individuals With Type 1 Diabetes
Lead sponsor
University of California, San Diego
Phase
Phase 1
Overall status
Completed
Start date
October 8, 2018
Completion date
November 30, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type1 diabetes mellitus